Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380315 | 1.00 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2380317 | 1.00 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2381805 | 1.00 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2381801 | 1.00 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL9405647 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL16314440 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL9405664 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL13992039 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL31365567 | 0.84 | — | — | |
| SCHEMBL17267078 | 0.83 | SHBG (0.30) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0421774-B1 | Process for production of optically active 2-(tetrahydropyran-2-yloxy)-1-propanol | TAKASAGO PERFUMERY CO LTD (JP) | 1994-06-15 | — | — | EP | claimed |
| US-5128489-A | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-(TETRAHYDROPYRAN-2-YLOXY)-1-PROPANOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1992-07-07 | — | — | US | claimed |
| EP-0421774-A2 | Process for production of optically active 2-(tetrahydropyran-2-yloxy)-1-propanol | Takasago International Corporation (JP) | 1991-04-10 | — | — | EP | claimed |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034106-A1 | Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics | UNIV DARMSTADT TECH (DE) | 2026-02-05 | — | — | US | disclosed |
| EP-4686495-A1 | MACROCYCLIC LIGANDS FOR FK506-BINDING PROTEINS FOR TREATMENT OF DISEASES WITH IMPROVED CHARACTERISTICS | Technische Universität Darmstadt (DE) | 2026-02-04 | — | — | EP | disclosed |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| EP-4531849-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-0368410-A2 | Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation | GIST-BROCADES N.V. (NL) | 1990-05-16 | — | — | EP | disclosed |
| EP-0357850-A1 | Polymer composition, capable of forming a chiral nematic mesophase | STAMICARBON B.V. (NL) | 1990-03-14 | — | — | EP | disclosed |
| US-4879292-A | Certain-phenoxy-phenoxy-alkylene-oxy-pyrimidines or symmetrical triazines, thio-analogues thereof, having insecticidal activity | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0128648-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-08-17 | — | — | EP | disclosed |
| US-4751225-A | Certain 2-pyridyloxy-lower alkylene-oxy-phenoxy compounds, thio-and methylene analogues having insecticidal properties | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0128648-A1 | Nitrogen-containing heterocyclic compounds, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
| US-4029693-A | HYPOTENSIVES, ANTISECRETORY, ANTIFERTILITY | THE UPJOHN COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4026909-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-3987072-A | CIS-4,5-Didehydro-15- or 16-alkylated 11-deoxy-PGE1 analogs | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | MEN1 3953/4885KMT2A 1716/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | MEN1 3953/4885KMT2A 1716/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | MEN1 2858/4885KMT2A 1790/4885 |
| US-20260034106-A1 | Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics | FKBP3, FKBP2, FKBP1B | MEN1 2691/4885KMT2A 4732/4885 |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI6, PADI2 | MEN1 3184/4885KMT2A 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.